Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Neurocrine Biosciences, Inc., Kymera Therapeutics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Neurocrine Biosciences, Inc., Kymera Therapeutics and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Neurocrine Biosciences, Inc., Kymera Therapeutics and Inc.

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer’s disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Latest Biotechnology and Neurocrine Biosciences, Inc., Kymera Therapeutics, Inc. Stock News

As of August 20, 2026, Neurocrine Biosciences, Inc. had a $15.5 billion market capitalization, compared to the Biotechnology median of $286.3 million. Neurocrine Biosciences, Inc.’s stock is up 9.1% in 2026, up 1.3% in the previous five trading days and up 15.15% in the past year.

Currently, Neurocrine Biosciences, Inc.’s price-earnings ratio is 22.4. Neurocrine Biosciences, Inc.’s trailing 12-month revenue is $3.4 billion with a 20.9% net profit margin. Year-over-year quarterly sales growth most recently was 39.5%. Analysts expect adjusted earnings to reach $10.189 per share for the current fiscal year. Neurocrine Biosciences, Inc. does not currently pay a dividend.

As of August 20, 2026, Kymera Therapeutics, Inc. had a $10.1 billion market cap, putting it in the 77th percentile of all stocks. Kymera Therapeutics, Inc.’s stock is up 58.4% in 2026, up 5% in the previous five trading days and up 185.55% in the past year.

Currently, Kymera Therapeutics, Inc. does not have a price-earnings ratio. Kymera Therapeutics, Inc.’s trailing 12-month revenue is $105.0 million with a -285.3% net profit margin. Year-over-year quarterly sales growth most recently was 465.2%. Analysts expect adjusted earnings to reach $-3.798 per share for the current fiscal year. Kymera Therapeutics, Inc. does not currently pay a dividend.

How We Compare Neurocrine Biosciences, Inc., Kymera Therapeutics and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Neurocrine Biosciences, Inc., Kymera Therapeutics and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Neurocrine Biosciences, Inc., Kymera Therapeutics and Inc. Stock Value Grades

Company	Ticker	Value
Neurocrine Biosciences, Inc.	NBIX	D
Kymera Therapeutics, Inc.	KYMR	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Neurocrine Biosciences, Inc. has a Value Score of 26, which is Expensive. Kymera Therapeutics, Inc. has a Value Score of 2, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither Neurocrine Biosciences, Inc., Kymera Therapeutics or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Neurocrine Biosciences, Inc., Kymera Therapeutics or Inc. is the better investment when it comes to value.

Neurocrine Biosciences, Inc., Kymera Therapeutics and Inc. Growth Grades

Company	Ticker	Growth
Neurocrine Biosciences, Inc.	NBIX	B
Kymera Therapeutics, Inc.	KYMR	F

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Neurocrine Biosciences, Inc. has a Growth Score of 69, which is Strong. Kymera Therapeutics, Inc. has a Growth Score of 10, which is Very Weak.

The Growth Grade Winner: Neurocrine Biosciences, Inc.

As you can clearly see from the Growth Grade breakdown above, Neurocrine Biosciences, Inc. has a more attractive growth grade than Kymera Therapeutics, Inc.. For investors who focus solely on how a company is growing relative to other companies in the same industry, Neurocrine Biosciences, Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Neurocrine Biosciences, Inc., Kymera Therapeutics and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Neurocrine Biosciences, Inc.	NBIX	C
Kymera Therapeutics, Inc.	KYMR	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Neurocrine Biosciences, Inc. has a Earnings Estimate Score of 47, which is Neutral. Kymera Therapeutics, Inc. has a Earnings Estimate Score of 31, which is Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Neurocrine Biosciences, Inc., Kymera Therapeutics or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Neurocrine Biosciences, Inc., Kymera Therapeutics or Inc. is the better investment when it comes to estimate revisions.

Other Neurocrine Biosciences, Inc., Kymera Therapeutics and Inc. Grades

In addition to Estimate Revisions, Value and Growth, A+ Investor also provides grades for Momentum and Quality.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Neurocrine Biosciences, Inc., Kymera Therapeutics and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Neurocrine Biosciences, Inc., Kymera Therapeutics or Inc. Stock?

Overall, Neurocrine Biosciences, Inc. stock has a Value Score of 26, Growth Score of 69 and Estimate Revisions Score of 47.

Kymera Therapeutics, Inc. stock has a Value Score of 2, Growth Score of 10 and Estimate Revisions Score of 31.

Comparing Neurocrine Biosciences, Inc., Kymera Therapeutics and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.